Welcome to the international HTA database
Showing [23537 Records] Selected Records [0 Hits] [Clear]
| Year | Source | Title | |
|---|---|---|---|
| 2007 | Canadian Agency for Drugs and Technologies in Health (CADTH) | Portable home hemodialysis for kidney failure | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Dasatinib (Sprycel®) for the treatment of Lymphoid blast CML and PH+ ALL | |
| 2007 | Technology Assessment Unit of the McGill University Health Centre (MUHC) | The use of image-free computer-assisted systems in total knee replacement surgeries | |
| 2007 | HAYES, Inc. | Paclitaxel (Taxol) for adjuvant and neoadjuvant treatment of breast cancer | |
| 2007 | Canadian Agency for Drugs and Technologies in Health (CADTH) | Human papillomavirus (HPV) vaccines: A Canadian update | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Dasatinib (Sprycel®) for the treatment of chronic, accelerated or blast phase chronic myeloid leukaemia | |
| 2007 | Technology Assessment Unit of the McGill University Health Centre (MUHC) | Drotrecogin alfa (activated) in severe sepsis | |
| 2007 | HAYES, Inc. | Paclitaxel (Taxol) for treatment of metastatic breast cancer | |
| 2007 | Canadian Agency for Drugs and Technologies in Health (CADTH) | Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1 | |
| 2007 | Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS) | Pedometer and accelerometer in assessing physical activity among children and adolescents | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Vinorelbine (Navelbine Oral®) | |
| 2007 | HAYES, Inc. | Pediatric bariatric surgery for morbid obesity | |
| 2007 | HAYES, Inc. | Quadramet (samarium Sm-153 lexidronam) (Cytogen Corp.) for treatment of bone pain due to osteoblastic metastatic bone cancer | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Idursulfase (Elaprase®) | |
| 2007 | VA Technology Assessment Program (VATAP) | Surgical treatments for morbid obesity- laparoscopic adjustable gastric banding: update 2007 | |
| 2007 | HAYES, Inc. | Positron emission tomography (PET) for alzheimer's disease (AD) | |
| 2007 | HAYES, Inc. | Quantitative electroencephalogram (QEEG) for evaluation of depression | |
| 2007 | VA Technology Assessment Program (VATAP) | Bladder cancer surveillance | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Agalsidase alfa (Replagal®) | |
| 2007 | New Zealand Health Technology Assessment (NZHTA) | Surveillance of women at high risk of breast cancer: a tech brief | |
| 2007 | Quality Improvement Scotland (NHS QIS ) | Pemetrexed for the treatment of non-small-cell lung cancer | |
| 2007 | HAYES, Inc. | Progesterone for the prevention of preterm birth | |
| 2007 | Institute of Health Economics (IHE) | Evidence of benefit from telemental health applications: a systematic review | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Sunitinib (Sutent®) | |
| 2007 | German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) | [Interventions for enhancing medication compliance/adherence with benefits in treatment outcomes] | |
| 2007 | Blue Cross Blue Shield Association (BCBS) | Special report: The efficacy and safety of statins in the elderly | |
| 2007 | Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) | Diagnostic performance of imaging techniques used for the preoperative locoregional staging of rectal cancer: a systematic review | |
| 2007 | Quality Improvement Scotland (NHS QIS ) | Determining the most clinically and cost effective way of implementing digital mammography services for breast screening in NHS Scotland | |
| 2007 | HAYES, Inc. | Rapid antibody testing for HIV | |
| 2007 | Institute of Health Economics (IHE) | The use of videoconferencing for mental health services in Canada and Finland | |
| 2007 | HAYES, Inc. | Radiation therapy for prevention of keloid scarring | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Darunavir (Prezista®) | |
| 2007 | Blue Cross Blue Shield Association (BCBS) | Laparoscopic adjustable gastric banding for morbid obesity | |
| 2007 | Technology Assessment Unit of the McGill University Health Centre (MUHC) | Pulsatile machine perfusion compared to cold storage in kidney preservation | |
| 2007 | Quality Improvement Scotland (NHS QIS ) | The clinical and cost effectiveness of thromboelastography/thromboelastometry | |
| 2007 | HAYES, Inc. | Silver-coated urinary catheters for prevention of urinary tract infections | |
| 2007 | Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) | Description of cancer screening in Spain. DESCRIC Project | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Tipranavir (Aptivus®) | |
| 2007 | Quality Improvement Scotland (NHS QIS ) | The use of recombinant factor VIIa (rFVIIa) in people with haemophilia who develop inhibitors | |
| 2007 | Quality Improvement Scotland (NHS QIS ) | Computed Tomography (CT) colonography | |
| 2007 | HAYES, Inc. | Tandem mass spectrometry for metabolic disease screening of newborns | |
| 2007 | Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) | Development of process and outcomes indicators, and assessment of oncology health care practice | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Co-careldopa intestinal gel (Duodopa®) | |
| 2007 | Quality Improvement Scotland (NHS QIS ) | Safety and risk associated with free standing midwife led maternity units (MLMU) | |
| 2007 | Quality Improvement Scotland (NHS QIS ) | Screening tools, detoxification and vitamin supplementation for alcohol dependence | |
| 2007 | HAYES, Inc. | Total ankle replacement | |
| 2007 | Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) | State of knowledge on the Coughassist (TM) (from Emerson), a mechanical system for clearance of bronchial secretions | |
| 2007 | Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) | Description of the current status of the prenatal screening of the most frequent fetal chromosomal diseases -especially Down's Syndrome- in Spain, and proposals for improvement of everyday clinical practice | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Dexrazoxane (Savene®) | |
| 2007 | Andalusian Health Technology Assessment Area (AETSA) | [Outcomes of treatments for stuttering] | |
| 2007 | Quality Improvement Scotland (NHS QIS ) | Cardiac resynchronisation therapy for the treatment of heart failure | |
| 2007 | HAYES, Inc. | Transurethral microwave thermotherapy | |
| 2007 | Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) | Development of the methodology and pilot implementation of prosthetic implant registers in the National Health system | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Clofarabine (Evoltra®) | |
| 2007 | Andalusian Health Technology Assessment Area (AETSA) | Guide for decision-making on the introduction of new genetic tests in the National Health System (GEN Guide) | |
| 2007 | Quality Improvement Scotland (NHS QIS ) | Carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma | |
| 2007 | HAYES, Inc. | Ultrasound-enhanced transcutaneous drug delivery | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Emtricitabine (Emtriva®) | |
| 2007 | Canadian Agency for Drugs and Technologies in Health (CADTH) | Short-acting insulin analogues for diabetes mellitus: meta-analysis of clinical outcomes and assessment of cost-effectiveness | |
| 2007 | Andalusian Health Technology Assessment Area (AETSA) | Update of the guide for the acquisition of new technologies | |
| 2007 | Quality Improvement Scotland (NHS QIS ) | Alteplase for the treatment of acute ischaemic stroke | |
| 2007 | Canadian Agency for Drugs and Technologies in Health (CADTH) | Diagnostic performance and costeffectiveness of technologies to measure bone mineral density in postmenopausal women | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Emtricitabine/tenofovir DF (Truvada®) | |
| 2007 | Andalusian Health Technology Assessment Area (AETSA) | Update of the guidance for the introduction of new drugs | |
| 2007 | Quality Improvement Scotland (NHS QIS ) | Varenicline for smoking cessation | |
| 2007 | NIHR Horizon Scanning Centre (NIHR HSC) | Golimumab (CNTO-148) for ankylosing spondylitis | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Parathyroid hormone (PTH) (Preotact®) | |
| 2007 | Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) | [Place of hyperbaric oxygen therapy in the management of cerebral palsy] | |
| 2007 | Andalusian Health Technology Assessment Area (AETSA) | The efficacy of acupuncture in the management of chronic pain and in palliative care. | |
| 2007 | Quality Improvement Scotland (NHS QIS ) | Adalimumab for the treatment of psoriatic arthritis | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Use of sorafenib (Nexavar®) for advanced renal cell carcinoma within NHS Wales | |
| 2007 | Andalusian Health Technology Assessment Area (AETSA) | [Update of the guide for the introduction of new drugs (GINF)] | |
| 2007 | Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) | [Tandem mass spectrometry and neonatal blood screening in Quebec] | |
| 2007 | Andalusian Health Technology Assessment Area (AETSA) | The therapeutic utility of growth factors in hepatic regeneration | |
| 2007 | Quality Improvement Scotland (NHS QIS ) | Rituximab for the treatment of rheumatoid arthritis | |
| 2007 | Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) | Economic evaluation of HPV vaccination in Austria | |
| 2007 | HAYES, Inc. | Robotically assisted atrial septal defect repair (da Vinci Surgical System) (Intuitive Surgical Inc.) | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Use of alglucosidase alfa (Myozyme™) within NHS Wales | |
| 2007 | Andalusian Health Technology Assessment Area (AETSA) | Use of recombinant human erythropoietin in orthopedic surgery | |
| 2007 | Quality Improvement Scotland (NHS QIS ) | Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis | |
| 2007 | Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) | Neonatal care of low-risk newborns. An approach to evidence-based health care planning in Styria | |
| 2007 | HAYES, Inc. | Dermoscopy for detection of melanoma | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Use of sodium phenylbutyrate within NHS Wales | |
| 2007 | Andalusian Health Technology Assessment Area (AETSA) | Intraperitoneal chemotherapy in advanced epithelial ovarian cancer | |
| 2007 | Quality Improvement Scotland (NHS QIS ) | Bortezomib monotherapy for relapsed multiple myeloma | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Laronidase (Aldurazyme®) | |
| 2007 | Andalusian Health Technology Assessment Area (AETSA) | Clinical applications of proteomic techniques | |
| 2007 | The Swedish Council on Health Technology Assessment (SBU) | Light therapy for depression, and other treatment of seasonal affective disorder | |
| 2007 | HAYES, Inc. | Robotically assisted mitral valve repair (da Vinci Surgical System) (Intuitive Surgical Inc.) | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Enfuvirtide | |
| 2007 | Andalusian Health Technology Assessment Area (AETSA) | Positron Emission Tomography combined with Magnetic Resonance (PET/RM) | |
| 2007 | The Swedish Council on Health Technology Assessment (SBU) | Benefits and risks of fortifying flour with folic acid to reduce the risk of neural tube defects | |
| 2007 | HAYES, Inc. | DISC nucleoplasty (ArthroCare Perc-D SpineWand) for percutaneous disc decompression | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Anagrelide (Xagrid®) | |
| 2007 | The Swedish Council on Health Technology Assessment (SBU) | [Peripheral arterial disease - diagnosis and treatment] | |
| 2007 | Institute for Clinical Effectiveness and Health Policy (IECS) | Percutaneous hallux valgus surgical correction | |
| 2007 | Andalusian Health Technology Assessment Area (AETSA) | Universal leukorreduction. A systematic review of the literature and an economic assessment | |
| 2007 | The Swedish Council on Health Technology Assessment (SBU) | Dyspepsia and gastro-oesophageal reflux | |
| 2007 | German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) | [Efficacy and effectiveness of recombinant human activated protein C in severe sepsis of adults] | |
| 2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Use of iloprost trometamol (Ventavis®) within NHS Wales |